Skip to main content

Advertisement

Table 2 “Screen positive” copy number variations (CNVs) in 13 cancer cases and two controls mapped to reported gains and losses in the Integrated Genomic Analysis of Ovarian Cancer (IGAOC) study [11]

From: Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening

Subject number Age (years) Study group FIGO Stage Percept™ call for aneuploidy Detected CNVs ≥ 15 Mb mapped according to IGAOCa
  Highly specific Moderately specific Non-specific
1 76 Early stage cancer 2C No call Chr 3q gain
Chr 12p gain
Chr 20q terminal gain
Chr 5q segmental loss
Chr 8p loss
Chr 9p loss
  Chr 5p gain
Chr 7q segmental loss
2 65 Early stage cancer 2C No call Chr 3q terminal gain
Chr 20 gain
Chr 4q loss
Chr 7p loss
Chr 13q segmental loss
Chr 15q segmental loss
Chr 6p gain Chr 2q interstitial gain
Chr 18q segmental gain
3 48 Early stage cancer 1C Low risk Chr 12p terminal gain   
4 71 Early stage cancer 2C Low risk Chr 3q interstitial gain
Chr 8q gain
  
5 38 Early stage cancer 1C Low risk Chr 8q terminal gain   Chr 3p terminal gain
6 47 Early stage cancer 2A Low risk Chr 8q terminal gain   
7 54 Advanced stage cancer 4 No call Chr 3q terminal gain
Chr 8 gain
Chr 5q loss
Chr 13 loss
Chr 15 loss
Chr 17 loss
Chr 18 loss
Chr 22 loss
Chr 14 loss Chr 5p gain
Chr 9p gain
8 57 Advanced stage cancer 3B Low risk Chr 8q terminal gain
Chr 8p terminal loss
Chr 1q interstitial gain
Chr 6p gain
Chr 1p interstitial gain
Chr 11q segmental gain
9 60 Advanced stage cancer 3A1 Low risk Chr 20 gain   
10 83 Advanced stage cancer 3A Low risk    Chr 11q interstitial gain
11 33 Advanced stage cancer 3C No call Chr 8q terminal gain
Chr 12p terminal gain
Chr 4q segmental loss
Chr 5q interstitial loss
Chr 6q terminal loss
Chr 8p loss
Chr 9p terminal loss
Chr 13 segmental loss
Chr 15 segmental loss
Chr 17q segmental loss
Chr 22 loss
Chr 6p segmental gains
Chr 7q segmental gains
Chr 1p segmental gains
Chr 2 segmental gains
Chr 5p gain
Chr 11q interstitial gain
Chr 18q segmental gain
Chr 1p segmental loss
Chr 10p loss
Chr 11q terminal loss
Chr 21 loss
12 58 Advanced stage cancer 3C No call Chr 3q gain
Chr 4p loss
Chr 9q loss
Chr 13 loss
Chr 1q gain
Chr 6p gain
Chr 7q terminal gain
Chr 11p loss
Chr 5p loss
Chr 7p terminal loss
Chr 10p gain
Chr 18 gain
13 66 Advanced stage cancer 3C Monosomy 18 Chr 20q gain
Chr 8q terminal segmental gain
  
14 44 Benign control NA Low risk Chr 20q segmental gain   
15 53 Benign control NA Low risk Chr 20q gain   
  1. aCNVs are categorized according to IGAOC analysis [8]. The IGAOC found 8 significantly gained chromosome arms (5 present in > 50 % of tumor samples), and 22 significantly deleted chromosome arms (18 present in > 50 %). We used the following definitions: highly specific CNV, statistically significant gain or loss (q value < 0.25) with frequency in > 50 %; Moderately specific CNV, statistically significant gain or loss (q value < 0.25) with frequency in < 50 %; non-specific CNV, gain or loss with q value > 0.25